Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
2006 1
2007 1
2023 2
2024 19
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Anti-Glomerular Basement Membrane Disease: Recent Updates.
Bharati J, Jhaveri KD, Salama AD, Oni L. Bharati J, et al. Adv Kidney Dis Health. 2024 May;31(3):206-215. doi: 10.1053/j.akdh.2024.04.007. Adv Kidney Dis Health. 2024. PMID: 39004460 Free article. Review.
Atypical forms of the disease are reported along with preceding triggers, such as immune checkpoint inhibitors, immunomodulatory drugs, and vaccines. Kidney outcomes in anti-glomerular basement membrane disease remain poor despite significant improvement in patient surviva …
Atypical forms of the disease are reported along with preceding triggers, such as immune checkpoint inhibitors, immunomodulatory drugs …
EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update.
Fanouriakis A, Kostopoulou M, Anders HJ, Andersen J, Aringer M, Beresford MW, Doria A, Frangou E, Furie R, Gladman DD, Houssiau F, Karras A, Kouloumas M, Madenidou AV, Malvar A, Marinaki S, Mok CC, Moroni G, Parodis I, Rednic S, Santos CS, Scire CA, Smolen JS, Tamirou F, Tanaka Y, Teng YKO, Welin E, Bertsias G, Boumpas DT. Fanouriakis A, et al. Ann Rheum Dis. 2026 Jan;85(1):75-90. doi: 10.1016/j.ard.2025.09.007. Epub 2025 Oct 16. Ann Rheum Dis. 2026. PMID: 41107121 Free article.
We performed systematic literature research (period January 2019 to March 2024), followed by the modified Delphi method, to form questions, elicit expert opinions, and reach consensus. ...CONCLUSIONS: The updated EULAR recommendations provide evidence- and expert-based con …
We performed systematic literature research (period January 2019 to March 2024), followed by the modified Delphi method, to form ques …
Intravenous maintenance fluid therapy in acutely and critically ill children: state of the evidence.
Brossier DW, Goyer I, Verbruggen SCAT, Jotterand Chaparro C, Rooze S, Marino LV, Schlapbach LJ, Tume LN, Valla FV; European Society of Paediatric and Neonatal Intensive Care-IV-MFT group. Brossier DW, et al. Lancet Child Adolesc Health. 2024 Mar;8(3):236-244. doi: 10.1016/S2352-4642(23)00288-2. Epub 2024 Jan 12. Lancet Child Adolesc Health. 2024. PMID: 38224704 Review.
IV-MFT is not typically treated in the same way as drugs with specific indications, contraindications, compositions, and associated adverse effects. ...
IV-MFT is not typically treated in the same way as drugs with specific indications, contraindications, compositions, and associated a …
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations.
Valdez BC, Tsimberidou AM, Yuan B, Baysal MA, Chakraborty A, Andersen CR, Andersson BS. Valdez BC, et al. Int J Mol Sci. 2024 Aug 26;25(17):9241. doi: 10.3390/ijms25179241. Int J Mol Sci. 2024. PMID: 39273190 Free PMC article.
We explored the synergistic cytotoxicity of histone deacetylase inhibitors (HDACis), poly(ADP-ribose) polymerase inhibitors (PARPis), and decitabine in breast (MDA-MB-231 and MCF-7) and ovarian (HEY-T30 and SKOV-3) cancer cell lines that were exposed to HDACi (panobinostat …
We explored the synergistic cytotoxicity of histone deacetylase inhibitors (HDACis), poly(ADP-ribose) polymerase inhibitors (PARPis), and de …
APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics.
Abushakra S, Porsteinsson AP, Sabbagh M, Watson D, Power A, Liang E, MacSweeney E, Boada M, Flint S, McLaine R, Kesslak JP, Hey JA, Tolar M. Abushakra S, et al. Alzheimers Dement (N Y). 2024 Aug 13;10(3):e12498. doi: 10.1002/trc2.12498. eCollection 2024 Jul-Sep. Alzheimers Dement (N Y). 2024. PMID: 39144121 Free PMC article.
RESULTS: The APOLLOE4 Phase 3 trial enrolled 325 subjects with a mean age of 69 years, 51% female, MMSE 25.6, and 65% mild cognitive impairment. Topline results are expected in 2024. DISCUSSION: APOLLOE4 is the first disease-modification AD trial focused on APOE epsilon4/e …
RESULTS: The APOLLOE4 Phase 3 trial enrolled 325 subjects with a mean age of 69 years, 51% female, MMSE 25.6, and 65% mild cognitive impairm …
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model.
Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, Tolar M. Hey JA, et al. Drugs. 2024 Jul;84(7):825-839. doi: 10.1007/s40265-024-02068-7. Epub 2024 Jun 20. Drugs. 2024. PMID: 38902572 Free PMC article. Clinical Trial.
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
Hey JA, Abushakra S, Blennow K, Reiman EM, Hort J, Prins ND, Sheardova K, Kesslak P, Shen L, Zhu X, Albayrak A, Paul J, Schaefer JF, Power A, Tolar M. Hey JA, et al. Drugs. 2024 Jul;84(7):811-823. doi: 10.1007/s40265-024-02067-8. Epub 2024 Jun 20. Drugs. 2024. PMID: 38902571 Free PMC article. Clinical Trial.
Nanostructured mesoporous silica carriers for platinum-based conjugates with anti-inflammatory agents.
Predarska I, Kaluđerović GN, Hey-Hawkins E. Predarska I, et al. Biomater Adv. 2024 Dec;165:213998. doi: 10.1016/j.bioadv.2024.213998. Epub 2024 Aug 19. Biomater Adv. 2024. PMID: 39236581 Free article. Review.
These agents are combined with platinum(II)-based antitumor drugs to create multifunctional platinum(IV) prodrugs, allowing for simultaneous delivery to tumor cells in a specific ratio. ...
These agents are combined with platinum(II)-based antitumor drugs to create multifunctional platinum(IV) prodrugs, allowing for simul …
Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV.
Hey M, Thompson L, Portwood C, Sexton H, Kumarendran M, Brandon Z, Kirtley S, Hemelaar J. Hey M, et al. AIDS. 2025 Feb 1;39(2):162-174. doi: 10.1097/QAD.0000000000004032. Epub 2024 Oct 15. AIDS. 2025. PMID: 39407417 Free PMC article.
CONCLUSION: The risks of adverse perinatal outcomes are higher among WHIV receiving ART compared with women without HIV, irrespective of the class of ART drugs. This underlines the need to further optimize ART in pregnancy and improve perinatal outcomes of WHIV....
CONCLUSION: The risks of adverse perinatal outcomes are higher among WHIV receiving ART compared with women without HIV, irrespective of the …
How to follow the guidelines, when the appropriate fluid is missing?
Brossier DW, Goyer I, Morice C, Alsohime F, Mayberry HF, Porcheret F, Tume LN, Valla FV; European Society of Pediatric and Neonatal Intensive Care (ESPNIC) IVMFT group. Brossier DW, et al. Eur J Pediatr. 2024 Jun;183(6):2797-2803. doi: 10.1007/s00431-024-05514-6. Epub 2024 Mar 18. Eur J Pediatr. 2024. PMID: 38498239 Free PMC article.
22 results